Synlogic Inc
SYBX
查看详细走势图
0.560USD
0.0000.00%
收盘 02/06, 16:00（美东）报价延迟15分钟
6.55M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
0.00%
5天
0.00%
1月
-54.10%
6月
-60.00%
今年开始到现在
-50.00%
1年
-58.21%
查看详细走势图
TradingKey Synlogic Inc股票评分
单位: USD 更新时间: 2026-01-20操作建议
Synlogic Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名223/396位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价1.00。中期看，股价处于下降通道。近一个月，市场表现非常差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Synlogic Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Synlogic Inc亮点
亮点风险
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
业绩增长期
公司处于发展阶段，最新年度总收入8.00K美元
估值低估
公司最新PE估值-2.14，处于3年历史低位
机构减仓
最新机构持股7.45M股，环比减少3.08%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值196.46K
分析师目标
根据
0
位分析师
--
评级
1.000
目标均价
-16.67%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Synlogic Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Synlogic Inc简介
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
公司代码SYBX
公司Synlogic Inc
CEO
网址https://www.synlogictx.com/
相关品种
